Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease
复制标题
DOI：
10.1007/s10072-018-3628-3
复制
发表时间：
2019-02-01
影响因子：
3.3
通讯作者：
Versino, Maurizio
中科院分区：
文献类型：
--
作者：
Bianchi, Maria Laura Ester;Riboldazzi, Giulio;Versino, Maurizio
本研究的主要终点是评价沙非酰胺对伴有运动波动的特发性帕金森病（PD）患者非运动症状（NMS）的影响。我们回顾性地收集了20例受特发性PD影响的受试者的数据，这些受试者单独使用左旋多巴或与多巴胺激动剂联合治疗，由于发生运动波动而开始使用沙非酰胺治疗。次要终点包括帕金森病结局量表（SCOPA）运动量表、认知评估、Hoehn和Yahr分期、帕金森病严重程度指数临床印象、医院焦虑和抑郁量表、身心疲劳、帕金森病睡眠量表、帕金森病问卷-8（PDQ-8）和EQ-5D。在基线和T1时进行这些量表/问卷中的每一个。对于疗效分析，使用平均值和标准差，采用描述性统计量处理连续变量。进行非参数检验（Friedman检验）以评价观察结果的统计学显著性。我们发现NMS的总分在统计学上显著降低，9个领域中有6个，30个项目中有13个。还检测到SCOPA运动量表、PDQ-8和CISI的统计学显著降低。总之，我们的数据显示了沙非酰胺对NMS的积极作用，并证实了其对运动神经病学的积极作用。
The primary endpoint of this work was to evaluate the effect of safinamide on non-motor symptoms (NMS) in patients affected by idiopathic Parkinson's disease (PD) complicated by motor fluctuations. We retrospectively collected data from 20 subjects affected by idiopathic PD in treatment with l-dopa alone or in combination with dopamine agonists, who began to be treated with safinamide due to the occurrence of motor fluctuations. Secondary endpoints included SCales for Outcomes in Parkinson's disease (SCOPA) Motor Scale, cognitive assessment, the Hoehn and Yahr stage, Clinical Impression of Severity Index for Parkinson's Disease, Hospital Anxiety And Depression Scale, Physical and Mental Fatigue, Parkinson's disease Sleep Scale, Parkinson's Disease Questionnaire-8 (PDQ-8) and EQ-5D. Each one of these scales/questionnaires was performed at baseline and T1. For efficacy analyses, continuous variables were treated with descriptive statistics, using mean and standard deviations. A non-parametric test (the Friedman test) was carried out to evaluate the statistical significance of the results observed. We found a statistically significant reduction of the total score of NMS, of 6 domains out of 9, and 13 items out of 30. A statistically significant reduction of SCOPA Motor Scale, PDQ-8, and CISI was also detected. In conclusion, our data showed a positive effect of safinamide on NMS and confirm its positive effect on motor symptomatology.